biostudies-literatureUnknown14(2)Nygaard B<h4>Objective</h4>Patients are increasingly using and requesting LT4/LT3 combination treatment for persistent hypothyroid symptoms, but the efficacy and side effects of long-term therapy remain largely unexplored. This study aimed to describe the patient group experiencing a long-lasting impact of LT4/LT3 and evaluate their quality of life (QoL) and hypothyroid symptoms.<h4>Method</h4>We performed a cross-sectional study of 66 hypothyroid patients who had previously initiated LT4/LT3 combination therapy. The patients were grouped by current treatment into patients still receiving LT4/LT3 treatment (T3 responders) and patients who had discontinued LT3 treatment due to lack of effect (T3 non-responders). ThyPRO was used to evaluate QoL, and a validated symptom score was used to assess hypothEuropean thyroid journale240275https://www.ebi.ac.uk/biostudies/studies/S-EPMC11906148biostudies-literatureLong-term outcomes of LT4/LT3 combination treatment for persistent hypothyroid symptoms.PMC11906148la Cour JLJensen CZMedici BRJorsal MNygaard BSteffensen RCarle AfalseLong-term outcomes of LT4/LT3 combination treatment for persistent hypothyroid symptoms.<h4>Objective</h4>Patients are increasingly using and requesting LT4/LT3 combination treatment for persistent hypothyroid symptoms, but the efficacy and side effects of long-term therapy remain largely unexplored. This study aimed to describe the patient group experiencing a long-lasting impact of LT4/LT3 and evaluate their quality of life (QoL) and hypothyroid symptoms.<h4>Method</h4>We performed a cross-sectional study of 66 hypothyroid patients who had previously initiated LT4/LT3 combination therapy. The patients were grouped by current treatment into patients still receiving LT4/LT3 treatment (T3 responders) and patients who had discontinued LT3 treatment due to lack of effect (T3 non-responders). ThyPRO was used to evaluate QoL, and a validated symptom score was used to assess hypoth2025-01-01T00:00:00Z2025 Apr2025-04-04T14:48:08.421Z2025-04-04T14:48:08.421ZS-EPMC119061483998280710.1530/ETJ-24-0275